Document Detail

Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
MedLine Citation:
PMID:  20429689     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Regression of left ventricular (LV) hypertrophy and albuminuria in hypertension has previously been shown to reduce clinical cardiovascular events and death. We aimed to investigate the associations of regression of electrocardiographic (ECG) LV hypertrophy and albuminuria with the incidence of revascularization. METHODS: In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen. The incidence of coronary and peripheral revascularization was recorded. RESULTS: In Cox regression analyses adjusted for treatment allocation and continent, high time-varying Sokolow-Lyon voltage (hazard ratio [HR]=1.01 [1.00-1.02], p=0.01), but not time-varying Cornell product or UACR, predicted coronary revascularization together with low time-varying HDL-cholesterol, low time-varying pulse pressure, high Framingham risk score and history of angina pectoris. Adjusted for treatment allocation and continent, high time-varying Sokolow-Lyon voltage (HR=1.01 [1.00-1.03], p=0.02), but not time-varying Cornell product or UACR, predicted peripheral revascularization together with high time-varying pulse pressure, high Framingham risk score, history of peripheral vascular disease and prior myocardial infarction. CONCLUSION: Higher Sokolow-Lyon voltage during antihypertensive treatment, but not UACR or the Cornell voltage-duration product, was independently associated with higher incidence of coronary as well as peripheral revascularization.
Camilla L Søraas; Kristian Wachtell; Peter M Okin; Björn Dahlöf; Richard B Devereux; Theis Tønnessen; Sverre E Kjeldsen; Michael H Olsen
Related Documents :
16857549 - Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicit...
7975129 - A nine-year chronic toxicity study of cadmium in monkeys. ii. effects of dietary cadmiu...
8299449 - Blood pressure, insulin, and c-peptide levels in san luis valley, colorado.
20299999 - Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic inter...
9100089 - Osteoarthritis as a determinant of an adverse coronary heart disease risk profile.
22320349 - Investigation of the haemodynamic effects of exenatide in healthy male subjects.
9839889 - Pituitary-adrenocortical effects of methoxamine infusion on halothane anaesthetised pon...
4074589 - Preoperative and postoperative pulmonary function tests in patients with atrial septal ...
10776359 - Perspectives on isolated systolic hypertension in elderly patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood pressure     Volume:  19     ISSN:  1651-1999     ISO Abbreviation:  Blood Press.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-20     Completed Date:  2010-08-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9301454     Medline TA:  Blood Press     Country:  England    
Other Details:
Languages:  eng     Pagination:  145-51     Citation Subset:  IM    
Oslo University Hospital, Ullevaal, Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / complications,  drug therapy,  urine
Angina Pectoris / complications,  drug therapy
Antihypertensive Agents / pharmacology,  therapeutic use
Atenolol / pharmacology,  therapeutic use
Blood Pressure / drug effects
Cholesterol, HDL
Electrocardiography / adverse effects
Hypertension* / complications,  drug therapy,  physiopathology
Hypertrophy, Left Ventricular / complications,  drug therapy*,  physiopathology*
Losartan / pharmacology,  therapeutic use
Regression Analysis
Reg. No./Substance:
0/Antihypertensive Agents; 0/Cholesterol, HDL; 114798-26-4/Losartan; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ablative erbium:YAG laser treatment of idiopathic chronic inflammatory non-cicatricial balanoposthit...
Next Document:  Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in tr...